CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CRISPR Therapeutics AGNASDAQ: CRSP
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $111.44M (cash outflow) rose 4.7% year over year, ahead of the -6.6% change in trailing-twelve-month net income. Sequentially, it rose 22.3% from the prior quarter. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Net income amounted to 16569.8% of revenue in FY2025, up 15523.3 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 15 analysts of -$441.15M (-24.1%) for the fiscal year ending Dec 2026, a slowdown from the +58.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$111.44M+22.3% QoQ
- Last fiscal yearDec 2025
- -$581.6M+58.8% YoY
- LTMSep 2026
- -$456.14M-6.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.7% | -13.3% | -18.0 pp |
| 1 year | +58.8% | -24.1% | -82.9 pp |
| 3-year CAGR | -3.6% | -28.0% | -24.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (581.6M) USD
- Year-over-year change
- -58.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (581.6M) | -58.8% |
| FY2024 | 2024-12-31 | (366.25M) | -138.4% |
| FY2023 | 2023-12-31 | (153.61M) | +76.4% |
| FY2022 | 2022-12-31 | (650.18M) | -272.2% |
| FY2021 | 2021-12-31 | 377.66M | — |
Net Income vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 net income of $456.14M is the 2nd largest of the 7 companies compared; the peer median is $199.48M.
- Its year-over-year change of -6.6% is the 4th highest of 7, against a peer median of -20.8%.
- Net income amounts to 1812.1% of revenue for CRSP, versus a peer median of 246.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $500.92M | -4.8% | +3.1% | 757.9% | |
| LTM Sep 2026 | $456.14M | -6.6% | -3.6% | 1812.1% | |
| LTM Mar 2026 | $297.87M | -36.9% | -47.0% | 210.8% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $108.95M | -56.6% | -10.1% | 281.6% | |
| LTM Jun 2026 | $85.43M | -78.6% | -34.8% | 54.7% | |
| LTM Mar 2026 | $43.6M | +98.3% | -25.7% | 96.7% | |
| Peer median (excluding CRSP) | $199.48M | -20.8% | -18.7% | 246.2% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 102.39M | 97.95M | 81.03M | 86.57M | 72.5M |
| Change in Working Capital | 26.86M | 19.85M | (193.59M) | 156.27M | 71.88M |
| Accounts Receivables | (161K) | 305K | (200M) | 175M | 25M |
| Inventory | (37.51M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 37.51M | 5.16M | (20.25M) | 0 | 44.89M |
| Other Working Capital | 27.02M | 14.38M | 26.66M | (18.73M) | 1.99M |
| Other Non-Cash Items | 14.11M | 12.47M | (14.05M) | (38.62M) | 72.73M |
| Operating Cash Flow | 538.97M | (495.74M) | (260.38M) | (142.77M) | (345.01M) |
| Capital Expenditures | (81.71M) | (37.19M) | (9.47M) | (1.9M) | (914K) |
| Acquisitions (Net) | 953.73M | 221.47M | 0 | 0 | 0 |
| Purchases of Investments | (1.51B) | (1.42B) | (1.07B) | (1.49B) | (1.01B) |
| Sales of Investments | 555.6M | 1.2B | 1.45B | 1.21B | 1.01B |
| Other Investing Activities | (953.73M) | (221.47M) | (2.5M) | 0 | (34M) |
| Investing Cash Flow | (1.04B) | (258.66M) | 374.65M | (280.48M) | (31.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 213.27M | 970K | 62.66M | 300.7M | 426.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.68M | 37.62M | 0 | 31.29M | 0 |
| Financing Cash Flow | 250.95M | 38.59M | 62.66M | 331.98M | 426.03M |
| Effect of Forex Changes | (11K) | (80K) | 656K | (21K) | 95K |
| Net Change in Cash | (245.52M) | (715.88M) | 177.59M | (91.29M) | 49.3M |
| Free Cash Flow | 457.27M | (532.93M) | (269.85M) | (144.68M) | (345.93M) |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.